Sera Prognostics (SERA) Competitors

$1.80 +0.04 (+2.27%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$1.73 -0.07 (-3.89%)

As of 08:55 AM Eastern

SERA vs. LFMD, BNR, BDSX, NAKA, and XGN

Should you buy Sera Prognostics stock or one of its competitors? MarketBeat compares Sera Prognostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sera Prognostics include LifeMD (LFMD), Burning Rock Biotech (BNR), Biodesix (BDSX), KindlyMD (NAKA), and Exagen (XGN). These companies are all part of the "healthcare" industry.

How does Sera Prognostics compare to LifeMD?

Sera Prognostics (NASDAQ:SERA) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sera Prognostics currently has a consensus price target of $5.00, suggesting a potential upside of 177.78%. LifeMD has a consensus price target of $9.14, suggesting a potential upside of 124.64%. Given Sera Prognostics' higher probable upside, equities research analysts plainly believe Sera Prognostics is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
LifeMD	2.37%	-150.88%	-22.59%

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A
LifeMD	$194.05M	1.01	$14.35M	$0.05	81.40

Sera Prognostics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

In the previous week, LifeMD's average media sentiment score of 0.00 beat Sera Prognostics' score of -1.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Negative
LifeMD	Neutral

Summary

LifeMD beats Sera Prognostics on 11 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Burning Rock Biotech?

Sera Prognostics (NASDAQ:SERA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Burning Rock Biotech has a net margin of -10.27% compared to Sera Prognostics' net margin of -56,385.97%. Burning Rock Biotech's return on equity of -9.98% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sera Prognostics currently has a consensus price target of $5.00, suggesting a potential upside of 177.78%. Given Sera Prognostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sera Prognostics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Burning Rock Biotech's average media sentiment score of 0.00 beat Sera Prognostics' score of -1.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Negative
Burning Rock Biotech	Neutral

Sera Prognostics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Sera Prognostics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A
Burning Rock Biotech	$77.16M	2.23	-$7.92M	-$0.79	N/A

Summary

Burning Rock Biotech beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Biodesix?

Sera Prognostics (NASDAQ:SERA) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Sera Prognostics has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A
Biodesix	$88.50M	1.73	-$35.26M	-$4.06	N/A

Sera Prognostics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Sera Prognostics currently has a consensus target price of $5.00, suggesting a potential upside of 177.78%. Biodesix has a consensus target price of $22.00, suggesting a potential upside of 44.93%. Given Sera Prognostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sera Prognostics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Biodesix	-33.26%	-2,101.40%	-35.65%

In the previous week, Biodesix had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Sera Prognostics. Biodesix's average media sentiment score of 0.00 beat Sera Prognostics' score of -1.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Negative
Biodesix	Neutral

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats Biodesix on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to KindlyMD?

Sera Prognostics (NASDAQ:SERA) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

KindlyMD has a net margin of -7,397.12% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
KindlyMD	-7,397.12%	-81.32%	-54.17%

In the previous week, KindlyMD had 4 more articles in the media than Sera Prognostics. MarketBeat recorded 4 mentions for KindlyMD and 0 mentions for Sera Prognostics. KindlyMD's average media sentiment score of -0.30 beat Sera Prognostics' score of -1.00 indicating that KindlyMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Negative
KindlyMD	Neutral

Sera Prognostics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, KindlyMD has a beta of 17.12, meaning that its share price is 1,612% more volatile than the broader market.

Sera Prognostics currently has a consensus price target of $5.00, indicating a potential upside of 177.78%. KindlyMD has a consensus price target of $0.75, indicating a potential upside of 352.90%. Given KindlyMD's higher probable upside, analysts clearly believe KindlyMD is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

54.6% of Sera Prognostics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 24.5% of KindlyMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sera Prognostics has higher earnings, but lower revenue than KindlyMD. Sera Prognostics is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A
KindlyMD	$3.92M	29.41	-$52.23M	-$1.08	N/A

Summary

KindlyMD beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Exagen?

Exagen (NASDAQ:XGN) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Exagen presently has a consensus target price of $9.25, indicating a potential upside of 116.63%. Sera Prognostics has a consensus target price of $5.00, indicating a potential upside of 177.78%. Given Sera Prognostics' higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

In the previous week, Exagen had 3 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Exagen and 0 mentions for Sera Prognostics. Exagen's average media sentiment score of 0.25 beat Sera Prognostics' score of -1.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Neutral
Sera Prognostics	Negative

75.3% of Exagen shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.55	-$19.95M	-$0.89	N/A
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A

Exagen has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Summary

Exagen beats Sera Prognostics on 11 of the 17 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68.92M	$8.21B	$6.34B	$12.29B
Dividend Yield	N/A	3.17%	2.79%	5.33%
P/E Ratio	-2.77	21.11	20.85	25.52
Price / Sales	1,236.60	21.28	546.15	84.26
Price / Cash	N/A	82.88	44.13	56.16
Price / Book	1.04	5.75	10.04	7.01
Net Income	-$31.93M	$180.93M	$3.55B	$335.27M
7 Day Performance	4.65%	6.67%	2.35%	1.16%
1 Month Performance	-15.89%	1.28%	-0.55%	0.09%
1 Year Performance	-4.26%	3.90%	36.42%	34.54%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
SERA Sera Prognostics	2.4969 of 5 stars	$1.80 +2.3%	$5.00 +177.8%	-6.2%	$68.92M	$57K	N/A	120
LFMD LifeMD	3.2386 of 5 stars	$4.30 +1.4%	$9.14 +112.6%	-62.2%	$205.06M	$194.05M	86.02	230
BNR Burning Rock Biotech	1.0758 of 5 stars	$16.85 +0.9%	N/A	+426.5%	$175.65M	$77.16M	N/A	1,390
BDSX Biodesix	3.176 of 5 stars	$13.94 -2.2%	$31.00 +122.4%	+92.1%	$144.05M	$88.50M	N/A	220
NAKA KindlyMD	3.1955 of 5 stars	$0.17 +0.4%	$0.75 +339.4%	N/A	$118.33M	$1.82M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. LFMD, BNR, BDSX, NAKA, and XGN

How does Sera Prognostics compare to LifeMD?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Summary

How does Sera Prognostics compare to Biodesix?

Summary

How does Sera Prognostics compare to KindlyMD?

Summary

How does Sera Prognostics compare to Exagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. LFMD, BNR, BDSX, NAKA, and XGN

How does Sera Prognostics compare to LifeMD?

Do institutionals and insiders hold more shares of SERA or LFMD?

Do analysts prefer SERA or LFMD?

Is SERA or LFMD more profitable?

Which has stronger valuation and earnings, SERA or LFMD?

Which has more volatility and risk, SERA or LFMD?

Does the media refer more to SERA or LFMD?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Is SERA or BNR more profitable?

Do insiders and institutionals hold more shares of SERA or BNR?

Do analysts prefer SERA or BNR?

Does the media refer more to SERA or BNR?

Which has more volatility and risk, SERA or BNR?

Which has preferable valuation and earnings, SERA or BNR?

Summary

How does Sera Prognostics compare to Biodesix?

Which has preferable valuation & earnings, SERA or BDSX?

Which has more volatility and risk, SERA or BDSX?

Do analysts recommend SERA or BDSX?

Is SERA or BDSX more profitable?

Does the media refer more to SERA or BDSX?

Do institutionals & insiders hold more shares of SERA or BDSX?

Summary

How does Sera Prognostics compare to KindlyMD?

Is SERA or NAKA more profitable?

Does the media refer more to SERA or NAKA?

Which has more volatility and risk, SERA or NAKA?

Do analysts rate SERA or NAKA?

Do institutionals & insiders believe in SERA or NAKA?

Which has stronger earnings and valuation, SERA or NAKA?

Summary

How does Sera Prognostics compare to Exagen?

Do analysts prefer XGN or SERA?

Is XGN or SERA more profitable?

Does the media prefer XGN or SERA?

Do insiders & institutionals have more ownership in XGN or SERA?

Which has higher earnings and valuation, XGN or SERA?

Which has more volatility and risk, XGN or SERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools